Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
T-alpha1 is able to reduce HBV replication in patients with chronic hepatitis B and is better tolerated than IFN-alpha and can gradually induce more sustained ALT normalization and HBV DNA and HBeAg loss. Expand
A Randomized, Controlled, Clinical Study of Thymosin Alpha‐1 Versus Interferon‐Alpha in Chinese Patients with Chronic Hepatitis B Lacking Hepatitis B Envelope Antigen
It is suggested that a 6‐month course of T‐ α1 therapy is effective and safe in patients with anti‐Hbe‐positive chronic hepatitis B; T‐α1 can reduce HBV replication in such patients. Expand
A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].
It is suggested that a 6-month course of T- alpha1 therapy is effective and safe in patients with anti-HBe-positive chronic hepatitis B; T-alpha1 can reduce HBV replication in such patients. Expand
PP-117 Thymosin alpha-1 therapy in Chinese patients with chronic hepatitis B: results from a randomized controlled clinical trial
Effects of hyperbaric oxygen on cellular immune function in the patients with stable chronic obstructive pulmonary disease
HBO therapy could significantly improve the cellular immune function of the patients with stable COPD, rectify hypoxia and carbon dioxide retention and improve pulmonary function. Expand